ReviewCurrent rheumatology reports2007
Outcome measures in systemic sclerosis: an update on instruments and current research.
Review in Current rheumatology reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.Arthritis and rheumatism · 2012Pooled it
- Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.Annals of the rheumatic diseases · 2020Trial
- Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials.Arthritis care & research · 2018Trial
- Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.Rheumatology (Oxford, England) · 2018Trial
- The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial.Annals of the rheumatic diseases · 2010Trial
- Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials.Rheumatology (Oxford, England) · 2009Trial
- Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.Arthritis and rheumatism · 2009Trial
- Adaptation and validation of the scleroderma skin patient-reported outcome questionnaire into Hungarian.Journal of patient-reported outcomes · 2026Article
- Capillaroscopic patterns are associated with interstitial lung disease, skin fibrosis, anti-Th/To antibodies and quality of life in systemic sclerosis: a prospective cross-sectional study.Frontiers in medicine · 2026Article
- Developing consensus outcome measures in juvenile systemic sclerosis: a global survey of pediatric rheumatologists and literature review.Pediatric rheumatology online journal · 2025Review
- Pulmonary artery wall thickness and systemic sclerosis: influence of inflammation on vascular changes.Turkish journal of medical sciences · 2025Article
- Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis.Arthritis research & therapy · 2024Article
- Skin Ultrasound Assessment of Patients with Systemic Scleroderma-An Observational Study.Journal of personalized medicine · 2024Article
- Association of pain and clinical factors on disability and quality of life in systemic sclerosis: A cross-sectional study from Turkish League Against Rheumatism Network.Archives of rheumatology · 2023Article
- Assessment of disease outcome measures in systemic sclerosis.Nature reviews. Rheumatology · 2022Review
- Skin model for improving the reliability of the modified Rodnan skin score for systemic sclerosis.BMC rheumatology · 2022Article
- Serum lysyl oxidase concentration increases in long-standing systemic sclerosis: Can lysyl oxidase change over time?Archives of rheumatology · 2022Article
- A Brazilian Cohort of Patients With Immuno-Mediated Chronic Inflammatory Diseases Infected by SARS-CoV-2 (ReumaCoV-Brasil Registry): Protocol for a Prospective, Observational Study.JMIR research protocols · 2020Article
- The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease.Respiratory research · 2020Review
- Validation of the suction device Nimble for the assessment of skin fibrosis in systemic sclerosis.Arthritis research & therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Substantial progress has been made in the past 10 years in the development and validation of outcome measures and refinement of trial methodology for systemic sclerosis (scleroderma, SSc). These advances in outcome measures have focused mostly on specific organ systems involved in SSc. Many of these new tools have been validated and subsequently adapted for use in multicenter clinical trials. Newer outcome measures in development are intended to more precisely quantify clinically meaningful change in specific organ systems, and some methods aim to assess overall disease burden in SSc. This review provides an update on currently used outcome measures in SSc with specific attention on newer tools and also describes methodology under development.
Indexed as
Identifiers
17502046What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.